Relevant to: All Medicare Advantage Organizations; Prescription Drug Plan Sponsors; Medicare-Medicaid Plans
This memorandum serves to remind Medicare Advantage (MA) organizations of CMS’s longstanding policy regarding Over-the-Counter (OTC) drug coverage as a supplemental benefit. CMS shares this reminder to complement a recent announcement from the Food and Drug Administration (FDA) regarding the approval of an OTC naloxone product, NARCAN®.